Floatz logo

18F-ASIS

Hepatic Tumors

University of MiamiN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hepatic Tumors cohort.

Asset / SponsorPhaseRating
Cobolimab
GlaxoSmithKline
Phase 1/2CCC
Dostarlimab
GlaxoSmithKline
Phase 1/2CCC

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
Thymus NeoplasmsDormant
CCC
Indicative ·
53 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →